Global Blood Therapeutics Inc.

+1.21 (+4.36%)
Products, Regulatory

Gbt's Oxbryta (Voxelotor) Receives Positive CHMP Opinion For Treatment Of Hemolytic Anemia In Patients With Sickle Cell Disease Aged 12 Years & Older

Published: 12/17/2021 15:43 GMT
Global Blood Therapeutics Inc. (GBT) - Gbt's Oxbryta (voxelotor) Receives Positive Chmp Opinion for Treatment of Hemolytic Anemia in Patients With Sickle Cell Disease Aged 12 Years & Older.
Global Blood Therapeutics - European Commission Decision on Marketing Authorization Anticipated Q1 of 2022.
Global Blood Therapeutics - Seeking Approval to Expand Potential Use of Oxbryta in U.S. for Treatment of Scd in Children As Young As 4 Years of Age.
Global Blood Therapeutics- If Approved by Ec, Oxbryta Will Receive Marketing Authorization in All Eu Member States, Iceland, Liechtenstein and Norway.
Global Blood Therapeutics Inc - Treatment With Oxbryta in the Hope Study Was Well Tolerated, With No New Safety Or Tolerability Findings Identified.